SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BJCT-BIOJECT-needle less injection product
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: geewiz who wrote (80)11/17/1997 12:37:00 PM
From: Marc Kahn  Read Replies (3) of 534
 
I see a lot to be happy about in the 98Q2 results. For the first time ever, product sales revenue (645K) exceeded manufacturing expense (593K). If sales volume continues to increase, average syringe price continues to rise, and manufacturing unit costs continue to decrease, profitability may not be far away.

Unit sales of syringes are very encouraging. The following numbers are for boxes of 100 syringes sold on a quarterly basis:

Qtr - Sold AvgPrice
97Q1 - 2062 $54
97Q2 - 4146 $55
97Q3 - 3303 $59
97Q4 - 2394 $55
98Q1 - 3611 $57
98Q2 - 8765 $60

Of course, Q2 is where most of the flu shot sales are realized. At the annual meeting, I had a discussion with Mike Redmond (VP Sales and Marketing). He told me their marketing efforts with other public health programs (besides flu shots) are starting to show positive results. He said that he was shooting for 700K product sales for Q3 and Q4, and thought that that could be done. For product sales to continue to expand in Q3 and Q4 would be a fantastic development!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News